ES2126606T3 - Terapia del sistema nervioso central mediante celulas modificadas geneticamente. - Google Patents

Terapia del sistema nervioso central mediante celulas modificadas geneticamente.

Info

Publication number
ES2126606T3
ES2126606T3 ES92925278T ES92925278T ES2126606T3 ES 2126606 T3 ES2126606 T3 ES 2126606T3 ES 92925278 T ES92925278 T ES 92925278T ES 92925278 T ES92925278 T ES 92925278T ES 2126606 T3 ES2126606 T3 ES 2126606T3
Authority
ES
Spain
Prior art keywords
nervous system
central nervous
therapy
cells
modified cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92925278T
Other languages
English (en)
Inventor
Fred Gage
Theodore Friedmann
Michael B Rosenberg
Jon A Wolff
Malcolm Schinstine
Michael D Kawaja
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California Berkeley
University of California, San Diego
Original Assignee
University of California Berkeley
University of California, San Diego
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California, San Diego filed Critical University of California Berkeley
Application granted granted Critical
Publication of ES2126606T3 publication Critical patent/ES2126606T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/33—Fibroblasts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/16—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with reduced pteridine as one donor, and incorporation of one atom of oxygen (1.14.16)
    • C12Y114/16002—Tyrosine 3-monooxygenase (1.14.16.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE EXPONEN METODOS PARA MODIFICACION GENETICA DE LAS CELULAS DEL DONANTE POR TRANSFERENCIA DE GENES CON INJERTO EN EL SISTEMA NERVIOSO CENTRAL PARA TRATAR CELULAS DEFECTUOSAS, ENFERMAS O DAÑADAS. LAS CELULAS MODIFICADAS DEL DONANTE PRODUCEN MOLECULAS FUNCIONALES QUE LLEVAN A CABO LA RECUPERACION O LA FUNCION MEJORADA DE LAS CELULAS DEL SNC. SE DESCRIBEN METODOS Y VECTORES PARA REALIZAR LA TRANSFERENCIA E INJERTO DEL GEN.
ES92925278T 1991-11-15 1992-11-13 Terapia del sistema nervioso central mediante celulas modificadas geneticamente. Expired - Lifetime ES2126606T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79289491A 1991-11-15 1991-11-15
CA002095300A CA2095300C (en) 1991-11-15 1993-04-30 Use of genetically modified cells to treat defects, disease or damage of the central nervous system
JP5136554A JPH06329559A (ja) 1991-11-15 1993-05-14 遺伝子的に修飾された細胞を移植して中枢神経系における欠陥、疾病、あるいは損傷を治療するための方法

Publications (1)

Publication Number Publication Date
ES2126606T3 true ES2126606T3 (es) 1999-04-01

Family

ID=27169416

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92925278T Expired - Lifetime ES2126606T3 (es) 1991-11-15 1992-11-13 Terapia del sistema nervioso central mediante celulas modificadas geneticamente.

Country Status (9)

Country Link
EP (1) EP0625195B1 (es)
JP (1) JPH06329559A (es)
AT (1) ATE175442T1 (es)
CA (1) CA2095300C (es)
DE (1) DE69228127T2 (es)
DK (1) DK0625195T3 (es)
ES (1) ES2126606T3 (es)
GR (1) GR3029362T3 (es)
WO (1) WO1993010234A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6103226A (en) * 1994-08-12 2000-08-15 Arch Development Corporation Genetically engineered cells that produce produce L. Dopa
US6294383B1 (en) 1994-11-08 2001-09-25 The Mclean Hospital Corporation Porcine neural cells and their use in treatment of neurological deficits due to neurodegenerative diseases
US6204053B1 (en) 1994-11-08 2001-03-20 Diacrin, Inc. Porcine cortical cells and their use in treatment of neurological deficits due to neurodegenerative diseases
WO1996022112A1 (en) 1995-01-17 1996-07-25 Genetic Therapy, Inc. Delivery of therapeutic agents by gene therapy
US5753505A (en) * 1995-07-06 1998-05-19 Emory University Neuronal progenitor cells and uses thereof
CA2245224A1 (en) 1998-08-14 2000-02-14 Jiang-Hong Giong Chemokine receptor antagonists and chemotherapeutics
DE69914463T2 (de) 1998-03-13 2004-11-11 The University Of British Columbia, Vancouver Therapeutische chemokine rezeptor antagonisten
CA2305787A1 (en) 2000-05-09 2001-11-09 The University Of British Columbia Cxcr4 antagonist treatment of hematopoietic cells
US6444205B2 (en) 1998-09-30 2002-09-03 Diacrin, Inc. Transplantation of neural cells for the treatment of chronic pain or spasticity
US6652864B1 (en) 1998-12-21 2003-11-25 Asilomar Pharmaceuticals, Inc. Compounds for intracellular delivery of therapeutic moieties to nerve cells
US20040120891A1 (en) 1998-12-21 2004-06-24 Craig Hill Compounds for intracellular delivery of therapeutic moieties to nerve cells
NZ514620A (en) * 1999-03-04 2004-04-30 Ppl Therapeutics Scotland Ltd Genetic modification of somatic cells and uses thereof
US20010038836A1 (en) * 2000-04-04 2001-11-08 Matthew During Application of myeloid-origin cells to the nervous system
US20050059584A1 (en) 2002-08-16 2005-03-17 Ahmed Merzouk Novel chemokine mimetics synthesis and their use
US7368425B2 (en) 2006-03-24 2008-05-06 Chemokine Therapeutics Corp. Cyclic peptides for modulating growth of neo-vessels and their use in therapeutic angiogenesis
US7378098B2 (en) 2000-04-12 2008-05-27 The University Of British Columbia CXC chemokine receptor 4 agonist peptides
US20030124095A1 (en) 2001-12-31 2003-07-03 Regents Of The University Of California Methods for therapeutic use of brain derived neurotrophic factor in the entorhinal cortex
KR101226702B1 (ko) * 2010-10-08 2013-01-25 충북대학교 산학협력단 인간 콜린 아세틸트랜스퍼라아제를 발현하는 인간 신경줄기세포 및 이의 용도
MX2021000644A (es) 2018-07-18 2021-08-19 Manzanita Pharmaceuticals Inc Conjugados para suministrar un agente contra el cancer a las celulas nerviosas, metodos de uso y metodos para la elaboracion de los mismos.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1008049A1 (en) * 1987-09-11 1999-04-30 Whitehead Institute For Biomedical Research Transduced fibroblasts and use therefor
US5082670A (en) * 1988-12-15 1992-01-21 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system
US6511823B1 (en) * 1990-08-20 2003-01-28 American Cyanamid Corporation Heparin binding neurotrophic factor gene sequence
WO1992009688A1 (en) * 1990-11-21 1992-06-11 Massachusetts Institute Of Technology MICE HAVING β2 MICROGLOBULIN GENE DISRUPTION

Also Published As

Publication number Publication date
JPH06329559A (ja) 1994-11-29
CA2095300A1 (en) 1994-10-31
WO1993010234A1 (en) 1993-05-27
GR3029362T3 (en) 1999-05-28
CA2095300C (en) 2002-06-25
EP0625195A1 (en) 1994-11-23
ATE175442T1 (de) 1999-01-15
DE69228127T2 (de) 1999-09-02
DK0625195T3 (da) 1999-08-30
EP0625195B1 (en) 1999-01-07
DE69228127D1 (de) 1999-02-18

Similar Documents

Publication Publication Date Title
ATE184797T1 (de) Transplantieren von genetisch modifizierten zellen zur behandlung von krankheiten des zentralen nervensystems
ATE175442T1 (de) Therapie des zentralnervensystems mit genetisch modifizierten zellen
Forman et al. Absence of H-2 antigens capable of reacting with cytotoxic T cells on a teratoma line expressing a T/t locus antigen.
BR9408435A (pt) Gene para dessaturase de ácido graxo vetor contendo o dito gene planta transformada com o dito gene e processo para criar a dita planta
GB8407572D0 (en) Dna vectors
ATE310077T1 (de) Erzeugung von hämatopoietischen zellen aus multipotenten neuronalen stammzellen
ATE132902T1 (de) Humane mangan-superoxiddismutase (hmn-sod)
ES2057102T5 (es) Dispositivo y metodo para separar leucocitos de un concentrado de plaquetas.
DK193788D0 (da) Fremgangsmaade til isolering af nucleinsyrer
PY990124A (es) Genes y vectores para conferir resistencia en plantas a los herbicidas
DK634386A (da) Vektorer til ekspression og sekretion af hirudin fra transformeret gaer
ES2084582T3 (es) Utilizacion de un elemento regulador anaerobico en plantas.
MX9702126A (es) Modelos in vitro de funcion y disfuncion del snc.
AR014256A1 (es) Plataforma de estiba ''pallet'' armable en material plastico.
ATE206761T1 (de) Plasmide zur herstellung von transgenen pflanzen welche in habitus und ertrag verändert sind
DE3689724D1 (de) Stabilisator für Energieversorgungssystem.
ES2104260T5 (es) Procedimiento para la fotocloracion de compuestos alquil-aromaticos.
ES2187047T3 (es) Composicion y metodo para la regulacion de la proliferacion celular y la muerte celular.
NO892029L (no) Fremgangsmaate ved spesifikk genetisk manipulering av mikroorganisme.
FR2710074B1 (fr) Gène GRB3-3, ses variants et leurs utilisations.
ES496049A0 (es) Sistema de produccion de energia electrica,mediante el aprovechamiento y control de la energia potencial de las aguas del mar
DK82591D0 (da) Saar-stimuleret dna-sekvens fra solanum tuberosum og dens anvendelse
ES2027374T3 (es) Perfeccionamientos en productos de tipo probiotico.
IT8748462A0 (it) Emulsioni di amidasi del tipo acqua in-olio
DK482686D0 (da) Promotoranordning til streptomycetes-vektorer

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 625195

Country of ref document: ES